112 related articles for article (PubMed ID: 14751132)
21. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.
Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y
Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681
[TBL] [Abstract][Full Text] [Related]
22. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.
Fujita M; Inoue M; Tanizawa O; Iwamoto S; Enomoto T
Cancer Res; 1992 Oct; 52(19):5323-8. PubMed ID: 1327506
[TBL] [Abstract][Full Text] [Related]
23. [Establishment of a HPV-negative cell line derived from xenografted human laryngeal squamous cell carcinoma].
Cai P; Wu ZY; Li JR; Liu GH; Hua QQ; Zhan HZ
Zhonghua Bing Li Xue Za Zhi; 2005 Aug; 34(8):533-6. PubMed ID: 16383303
[TBL] [Abstract][Full Text] [Related]
24. Papillary squamous cell carcinoma of the uterine cervix: an immunophenotypic appraisal of 12 cases.
Mirhashemi R; Ganjei-Azar P; Nadji M; Lambrou N; Atamdede F; Averette HE
Gynecol Oncol; 2003 Sep; 90(3):657-61. PubMed ID: 13678741
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical overexpression of p16 protein associated with cervical cancer in Thailand.
Jedpiyawongse A; Homcha-em P; Karalak A; Srivatanakul P
Asian Pac J Cancer Prev; 2008; 9(4):625-30. PubMed ID: 19256750
[TBL] [Abstract][Full Text] [Related]
26. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
[TBL] [Abstract][Full Text] [Related]
27. HPV infection and p16
Missaoui N; Mestiri S; Bdioui A; Zahmoul T; Hamchi H; Mokni M; Hmissa S
Pathol Res Pract; 2018 Apr; 214(4):498-506. PubMed ID: 29572122
[TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of a human-papillomavirus negative, p53-mutation negative human cervical cancer cell line.
Chou CY; Chen YH; Tzeng CC; Cheng YC; Chang CF; Chen TM
Cancer Lett; 1996 Apr; 102(1-2):173-81. PubMed ID: 8603367
[TBL] [Abstract][Full Text] [Related]
29. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation.
Nakao Y; Yang X; Yokoyama M; Ferenczy A; Tang SC; Pater MM; Pater A
Br J Cancer; 1997; 75(10):1410-6. PubMed ID: 9166931
[TBL] [Abstract][Full Text] [Related]
30. The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas of uterine cervix from India.
Munirajan AK; Kannan K; Bhuvarahamurthy V; Ishida I; Fujinaga K; Tsuchida N; Shanmugam G
Gynecol Oncol; 1998 Jun; 69(3):205-9. PubMed ID: 9648588
[TBL] [Abstract][Full Text] [Related]
31. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
32. The role of p53 inactivation in human cervical cell carcinoma development.
Miwa K; Miyamoto S; Kato H; Imamura T; Nishida M; Yoshikawa Y; Nagata Y; Wake N
Br J Cancer; 1995 Feb; 71(2):219-26. PubMed ID: 7841033
[TBL] [Abstract][Full Text] [Related]
33. Gene expression profiling in two morphologically different uterine cervical carcinoma cell lines derived from a single donor using a human cancer cDNA array.
Fujimoto T; Nishikawa A; Iwasaki M; Akutagawa N; Teramoto M; Kudo R
Gynecol Oncol; 2004 May; 93(2):446-53. PubMed ID: 15099960
[TBL] [Abstract][Full Text] [Related]
34. A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas.
Koyamatsu Y; Yokoyama M; Nakao Y; Fukuda K; Saito T; Matsukuma K; Iwasaka T
Gynecol Oncol; 2003 Sep; 90(3):547-51. PubMed ID: 13678722
[TBL] [Abstract][Full Text] [Related]
35. Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma--an in vivo and in vitro study.
Jouhi L; Datta N; Renkonen S; Atula T; Mäkitie A; Haglund C; Ahmed A; Syrjänen S; Grénman R; Auvinen E; Lehtonen S; Hagström J
Tumour Biol; 2015 Sep; 36(10):7755-64. PubMed ID: 25941114
[TBL] [Abstract][Full Text] [Related]
36. Mutations of p53 and human papillomavirus infection in cervical carcinoma.
Paquette RL; Lee YY; Wilczynski SP; Karmakar A; Kizaki M; Miller CW; Koeffler HP
Cancer; 1993 Aug; 72(4):1272-80. PubMed ID: 8393371
[TBL] [Abstract][Full Text] [Related]
37. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone.
Ishikawa H; Mitsuhashi N; Sakurai H; Maebayashi K; Niibe H
Cancer; 2001 Jan; 91(1):80-9. PubMed ID: 11148563
[TBL] [Abstract][Full Text] [Related]
38. Cervical squamous dysplasias and carcinomas with immunodetectable p53 frequently contain HPV.
Mittal KR; Lin O; Chan W; Goswami S; Demopoulos RI
Gynecol Oncol; 1995 Sep; 58(3):289-94. PubMed ID: 7672694
[TBL] [Abstract][Full Text] [Related]
39. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours.
Crook T; Wrede D; Tidy JA; Mason WP; Evans DJ; Vousden KH
Lancet; 1992 May; 339(8801):1070-3. PubMed ID: 1349102
[TBL] [Abstract][Full Text] [Related]
40. P53 codon 72 polymorphism and susceptibility to development of human papilloma virus-associated cervical cancer in Indian women.
Nagpal JK; Sahni S; Das BR
Eur J Clin Invest; 2002 Dec; 32(12):943-8. PubMed ID: 12534455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
